New drug HSK55879 enters first human safety trial

NCT ID NCT07521345

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 study tests the safety and tolerability of a new drug called HSK55879 in 46 healthy adults aged 18 to 45. Participants receive either the drug or a placebo, and researchers monitor side effects and how the drug moves through the body. The goal is to gather early safety data, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HSK55879

What could go wrong

This is a very early Phase 1 study in healthy people, so it cannot show any treatment benefit. The drug may prove unsafe or ineffective in later trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALHTY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Second Affiliated Hospital of Anhui Medical University

    RECRUITING

    Hefei, Anhui, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact